iRANO
Pronunciation: eye-RAH-no
Also written as: iRANO — Immunotherapy Response Assessment for Neuro-Oncology
Standardized criteria for evaluating treatment response in brain tumors receiving immunotherapy.
Full Definition
Immunotherapy Response Assessment for Neuro-Oncology (iRANO) represents specialized response criteria developed to address the unique patterns of response and progression seen with immunotherapy in central nervous system tumors. Unlike traditional chemotherapy, immunotherapy can cause delayed responses, pseudoprogression due to immune infiltration, and mixed responses. iRANO incorporates clinical assessment alongside imaging findings and recognizes that initial enlargement may not represent true progression. The criteria help distinguish between treatment-related inflammation and actual tumor progression, which is critical for appropriate treatment decisions in patients receiving checkpoint inhibitors or other immunotherapies for brain tumors.
Usage
Usage note: Specifically for neuro-oncology immunotherapy - distinguish from iRECIST for systemic disease.
In Context
- "The patient's imaging was evaluated using iRANO criteria given the immunotherapy treatment." — neuro-oncology report
- "iRANO guidelines recommend confirmatory imaging 4-6 weeks after initial progression." — clinical protocol